Covid-19 cases rise in US hotspots

Vaccine makers are preparing for a next possible phase of the Covid-19 vaccine rollout: booster doses.

The biopharmaceutical company Pfizer announced on Thursday that it has seen waning immunity from its coronavirus vaccine — although efficacy in preventing serious illness remains high — but did not detail the evidence. It said a third dose may be needed six to 12 months after full vaccination.
The company said it would publish “more definitive data soon” and in August would seek emergency use authorization from the US Food and Drug Administration for a booster dose.
But just hours after Pfizer made its announcement, the FDA and US Centers for Disease Control and Prevention issued a joint statement saying people who are fully vaccinated do not need booster shots yet.
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast
While boosters are not necessary now, more information is needed to decide whether people might eventually need booster doses of Covid-19 vaccines, and a rise in so-called breakthrough cases could offer a clue in the future, federal vaccine advisers said in June.
Members of the CDC’s Advisory Committee on Immunization Practices discussed when it might be time for the agency to make recommendations for booster doses and committee members mostly agreed that more data around the benefits of boosters is needed.
ACIP members agreed that a rise in “breakthrough” Covid-19 cases, which occur after someone has been fully vaccinated, could be a sign in the future that immunity is waning and booster doses of vaccine may be needed.

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: